fenofibrate has been researched along with eicosapentaenoic acid in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (10.00) | 18.2507 |
| 2000's | 3 (30.00) | 29.6817 |
| 2010's | 5 (50.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Auwerx, J; Berge, RK; Frøyland, L; Kryvi, H; Madsen, L; Staels, B; Totland, GK; Vaagenes, H | 1 |
| Hotta, O; Ieiri, N; Taguma, Y | 1 |
| Horiike, N; Iwai, M; Kanno, S; Matsui, H; Matsuura, B; Minami, H; Onji, M; Tsubouchi, E | 1 |
| Cao, JM; Clouet, P; Degrace, P; Demizieux, L; Du, ZY; Gresti, J; Liu, YJ; Moindrot, B; Tian, LX | 1 |
| Aoyama, T; Gonzalez, FJ; Horiuchi, A; Kanbe, H; Kono, H; Nakajima, T; Sugiyama, E; Tanaka, E; Tanaka, N; Zhang, X | 1 |
| Castillero, E; López-Calderón, A; López-Menduiña, M; Martín, AI; Villanúa, MÁ | 1 |
| Jacob, RF; Mason, RP | 1 |
| Preston Mason, R | 1 |
| Boch, T; Michaeli, DT; Michaeli, JC; Michaeli, T | 1 |
1 review(s) available for fenofibrate and eicosapentaenoic acid
| Article | Year |
|---|---|
New Insights into Mechanisms of Action for Omega-3 Fatty Acids in Atherothrombotic Cardiovascular Disease.
Topics: Atherosclerosis; Cell Membrane; Cholesterol, LDL; Coronary Thrombosis; Docosahexaenoic Acids; Eicosapentaenoic Acid; Endothelial Cells; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertriglyceridemia; Niacin; Risk Factors; Triglycerides | 2019 |
9 other study(ies) available for fenofibrate and eicosapentaenoic acid
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Mitochondrion is the principal target for nutritional and pharmacological control of triglyceride metabolism.
Topics: Animals; Docosahexaenoic Acids; Eicosapentaenoic Acid; Fenofibrate; Fish Oils; Humans; Hypolipidemic Agents; Liver; Male; Microbodies; Mitochondria, Liver; Oxidation-Reduction; Rabbits; Rats; Rats, Wistar; Triglycerides | 1997 |
Resolution of typical lipoprotein glomerulopathy by intensive lipid-lowering therapy.
Topics: Adult; Anticholesteremic Agents; Apolipoproteins E; Drug Combinations; Eicosapentaenoic Acid; Female; Fenofibrate; Humans; Hypolipidemic Agents; Kidney Diseases; Kidney Glomerulus; Lipids; Lipoproteins; Male; Microscopy, Electron; Nephrotic Syndrome; Niceritrol; Pedigree; Probucol | 2003 |
Effects of antihyperlipidemic agents on hepatic insulin sensitivity in perfused Goto-Kakizaki rat liver.
Topics: Animals; Diabetes Mellitus, Type 2; Eicosapentaenoic Acid; Fenofibrate; Glycogen; Hypoglycemic Agents; Hypolipidemic Agents; Insulin Resistance; Liver; Male; Models, Animal; Perfusion; Pioglitazone; Rats; Thiazolidinediones | 2004 |
Alteration of 20:5n-3 and 22:6n-3 fat contents and liver peroxisomal activities in fenofibrate-treated rainbow trout.
Topics: Animals; Carnitine O-Palmitoyltransferase; Catalase; Docosahexaenoic Acids; Eicosapentaenoic Acid; Fatty Acids; Fenofibrate; Hypolipidemic Agents; Lipid Metabolism; Lipids; Liver; Male; Malonyl Coenzyme A; Mitochondria, Liver; Muscles; Oncorhynchus mykiss; Oxidation-Reduction; Palmitates; Peroxisomes | 2004 |
Eicosapentaenoic acid improves hepatic steatosis independent of PPARα activation through inhibition of SREBP-1 maturation in mice.
Topics: Animals; Dietary Fats; Disease Models, Animal; Eicosapentaenoic Acid; Fatty Liver; Fenofibrate; Genotype; Immunoblotting; Lipid Peroxidation; Liver; Liver Function Tests; Male; Mice; Mice, Knockout; Oxidative Stress; PPAR alpha; Sterol Regulatory Element Binding Protein 1 | 2010 |
Comparison of the effects of the n-3 polyunsaturated fatty acid eicosapentaenoic and fenofibrate on the inhibitory effect of arthritis on IGF1.
Topics: Animals; Arthritis, Experimental; Base Sequence; Eicosapentaenoic Acid; Fenofibrate; Insulin-Like Growth Factor Binding Protein 3; Insulin-Like Growth Factor Binding Protein 5; Insulin-Like Growth Factor I; Liver; Male; Muscle, Skeletal; Muscular Atrophy; Rats; Rats, Wistar; RNA, Messenger | 2011 |
Eicosapentaenoic acid inhibits glucose-induced membrane cholesterol crystalline domain formation through a potent antioxidant mechanism.
Topics: Antioxidants; Atorvastatin; Cholesterol, LDL; Eicosapentaenoic Acid; Fenofibrate; Gemfibrozil; Glucose; Heptanoic Acids; Lipid Peroxidation; Lipid Peroxides; Membrane Lipids; Membranes, Artificial; Niacin; Pyrroles | 2015 |
Cost-Effectiveness of Icosapent Ethyl, Evolocumab, Alirocumab, Ezetimibe, or Fenofibrate in Combination with Statins Compared to Statin Monotherapy.
Topics: Antibodies, Monoclonal, Humanized; Cardiovascular Diseases; Cost-Benefit Analysis; Dyslipidemias; Eicosapentaenoic Acid; Ezetimibe; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Proprotein Convertase 9; Quality-Adjusted Life Years; State Medicine | 2022 |